Investors are weighing Pfizer’s stable dividend and oncology-focused growth strategy against the higher-risk, higher-reward potential of biotech firms. Pfizer is navigating a post-COVID revenue ...

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund ...

GeoVax CEO David Dodd highlights the need for U.S. manufacturing to reduce reliance on foreign biotech and strengthen ...

CRISPR Therapeutics proved the strength of its technology a couple of years ago when it won approval for its first product.

Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics ...

Nuvalent is positioned as a high-quality late-stage biotech with two near-commercial precision oncology assets. Read more on ...

Cochlear, CSL and Pro Medicus have been hard hit by disparate concerns, many of which investors suspect are structural rather ...

Earlier today, Nautilus Biotechnology released financial results for the quarter ended March 31, 2026. If you haven't received this news release or if you'd like to be added to the company's ...

Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this ...

Laguna Biotherapeutics, Inc. (Laguna), a clinical-stage biotechnology company focused on novel live bacterial therapeutics, ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting preclinical data from SG293, ...

Biopharma is rebounding across rare disease, oncology and neuroscience. Here, Cytokinetics achieved a rare milestone: a first ...